Snapshot from Nov 22, 2026 at 07:00 UTC. For live data and tracking: View Live
Other

Intismeran

Tracked across 1 events · 126 articles · First seen Aug 19, 2026 · Last active Aug 19, 2026

Sentiment
85
Attention
7
Events
1
Relationships
0
Live sentiment trends, attention charts, and prominence tracking available on the Ergen Dashboard
7 85
Tech
On August 19, 2026, Moderna and Merck announced that their personalized mRNA cancer vaccine, intismeran autogene, combined with Merck's immunotherapy Pembrolizumab, met its primary and secondary endpoints in a Phase 3 trial involving 1,137 patients…
Impact: Intismeran is the personalized mRNA vaccine that met trial endpoints; it is a potential blockbuster and key to Moderna's diversification.
Aug 19, 2026 · 126 articles
ERGEN INTELLIGENCE
Track Intismeran live

Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.